EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment

Kristin A Shimano, Amanda B Grimes, Shipra Kaicker, Sanjay J Shah, Elizabeth Gunn, Rukhmi V Bhat, Manpreet Kochhar, Jennifer A Rothman, Melissa J Rose, Michael Briones, Taizo A Nakano, Jeffrey D Lebensburger und 27 weitere

JAMA · 2025

DOI: 10.1001/jama.2025.18168 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, 2025. Verfasst von Kristin A Shimano und 38 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Benioff Children's Hospitals, San Francisco. Hauptthemen laut MEDLINE: Benzoates, Hydrazines, Purpura, Thrombocytopenic, Idiopathic, Pyrazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia is unknown.

Objective

To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed immune thrombocytopenia treated with eltrombopag than in those treated with standard therapy (first-line treatments). Design, Setting, and Participants This phase 3, randomized clinical trial enrolled patients (aged 1-<18 years) with newly diagnosed primary immune thrombocytopenia (platelet count <30 × 10 9 /L who required pharmacological treatment but did not have severe bleeding or need a rapid increase in platelet count) from May 7, 2019, to January 25, 2024, at 23 centers participating in the Pediatric ITP Consortium of North America. Final follow-up occurred on February 26, 2025.

Interventions

Eltrombopag was administered orally based on a standard dosing schedule (n = 78) vs standard therapy (investigator choice of glucocorticoids, intravenous immunoglobulin, or anti-D immunoglobulin) (n = 40). Main Outcomes and Measures The primary outcome was a sustained platelet response defined as 3 or more of 4 platelet counts greater than 50 × 10 9 /L during weeks 6 to 12 without rescue treatment. The secondary outcomes included bleeding scores, change in health-related quality of life, and serious adverse events.

Results

Of 118 pediatric patients (median age, 8 years [IQR, 4-12 years]; 49% were male), 63% experienced an initial treatment failure after observation or medical therapy. Enrollment ended after a planned interim analysis met a prespecified threshold for efficacy. Of 71 patients in the eltrombopag group, 46 (65% [95% CI, 54%-76%]) had a sustained platelet response compared with 13 of 37 patients (35% [95% CI, 20%-51%]) in the standard therapy group (between-group difference, 30% [95% CI, 11%-49%]; P = .002), which crossed the monitoring boundary for efficacy. Overall, there was no between-group difference in the number and type of adverse events. Conclusions and Relevance In pediatric patients with newly diagnosed immune thrombocytopenia requiring pharmacological treatment, eltrombopag resulted in a higher rate of sustained platelet response compared with standard therapy. Eltrombopag may be an effective option for pediatric patients with newly diagnosed immune thrombocytopenia with nonsevere bleeding who warrant medical intervention. Trial Registration ClinicalTrials.gov Identifier: NCT03939637

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoatesHydrazinesPurpura, Thrombocytopenic, IdiopathicPyrazolesReceptors, ThrombopoietinAdolescentChildChild, PreschoolFemaleHumansInfantMaleAdministration, OralGlucocorticoidsHemorrhageImmunoglobulins, IntravenousPlatelet CountProspective StudiesQuality of LifeRho(D) Immune GlobulinTreatment Outcome

Substanzen

BenzoateseltrombopagGlucocorticoidsHydrazinesImmunoglobulins, IntravenousPyrazolesReceptors, ThrombopoietinRho(D) Immune Globulin

Autor:innen und Institutionen

  • UCSF Benioff Children's Hospitals, San Francisco.
  • Texas Children's Cancer and Hematology Center, Houston.
  • Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
  • Weill Cornell Medicine/NewYork Presbyterian-Weill Cornell Medical College, New York, New York.
  • Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona.
  • Department of Child Health, College of Medicine, University of Arizona, Phoenix.

Zitieren

APA

Shimano, K. A., Grimes, A. B., Kaicker, S., Shah, S. J., Gunn, E., Bhat, R. V., Kochhar, M., Rothman, J. A., Rose, M. J., Briones, M., Nakano, T. A., Lebensburger, J. D., Lambert, M. P., Fritch Lilla, S. A., Jesudas, R., Lee-Miller, C. A., Thompson, A. A., Rifkin-Zenenberg, S., Majumdar, S., …, & Grace, R. F. (2025). Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment. JAMA. https://doi.org/10.1001/jama.2025.18168

Vancouver

Shimano KA, Grimes AB, Kaicker S, Shah SJ, Gunn E, Bhat RV, et al. Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment. JAMA. 2025. doi:10.1001/jama.2025.18168

BibTeX
@article{Shimano2025,
  author = {Shimano, Kristin A and Grimes, Amanda B and Kaicker, Shipra and Shah, Sanjay J and Gunn, Elizabeth and Bhat, Rukhmi V and Kochhar, Manpreet and Rothman, Jennifer A and Rose, Melissa J and Briones, Michael and Nakano, Taizo A and Lebensburger, Jeffrey D and Lambert, Michele P and Fritch Lilla, Stephanie A and Jesudas, Rohith and Lee-Miller, Cathy A and Thompson, Alexis A and Rifkin-Zenenberg, Stacey and Majumdar, Suvankar and Crary, Shelley E and Hege, Kerry and Ford, James B and Bies, Joshua J and Fort, John and Wynn, Tung T and Hsieh, Loan and Ruiz, Maritza E and Dinu, Bogdan and Wong, Julia M W and Kao, Pei-Chi and Kim, Taylor O and Arnold, Staci D and Bennett, Carolyn M and Despotovic, Jenny M and Klaassen, Robert J and Neufeld, Ellis J and Neunert, Cindy E and London, Wendy B and Grace, Rachael F},
  title = {Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment},
  journal = {JAMA},
  year = {2025},
  doi = {10.1001/jama.2025.18168}
}
Kostenlos starten →